| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000002961 |
| Receipt No. | R000003402 |
| Official scientific title of the study | Prospective, randomized, open-label, clinical trial comparing the effects of losartan (regular dose) /hydrochlorothiazide combination and losartan alone (high-dose) on blood pressure, endothelial function and markers for obesity/oxidative stress/chronic kidney diseases |
| Date of disclosure of the study information | 2010/01/03 |
| Last modified on | 2017/03/20 (Ver. 8) |
| Basic information | ||
| Official scientific title of the study | Prospective, randomized, open-label, clinical trial comparing the effects of losartan (regular dose) /hydrochlorothiazide combination and losartan alone (high-dose) on blood pressure, endothelial function and markers for obesity/oxidative stress/chronic kidney diseases | |
| Title of the study (Brief title) | Prospective, randomized, open-label, clinical trial comparing the effects of losartan/hydrochlorothiazide combination and losartan alone | |
| Region |
|
|
| Condition | ||
| Condition | Hypertension | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Comparison of losartan (standard dose)/hydrochlorothiazide combination and losartan alone (high dose) on blood pressure, endothelial function and levels of markers for inflammation/obesity/oxidative stress/early stage kidney diseases. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Blood pressure (Office/Home monitoring)
Flow-mediated vasodilation in forearm Heparin-releasable EC-SOD levels Twelve and Twenty four weeks after administration |
| Key secondary outcomes | Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria)
Twelve weeks and Twenty four after administration |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Administration of
losartan (standard dose)/hydrochlorothiazide combination |
|
| Interventions/Control_2 | Administration of losartan alone (high-dose) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Hypertensive patients whose blood pressures did not reach the levels recommended by Hypertension Guidelines 2009 of Japanese Association of Hypertension, even when administered standard doses of angiotensin receptor blokers.
2) Outpatients 3) Subjects who gave written informed consent |
|||
| Key exclusion criteria | 1)Allergy against
losartan/hydrochlorothiazide 2)Poor-controlled hypertension (DBP>110 mmHg) 3)Poor-controlled diabetes (HbA1c>8.0 %) 4)Secondary hypertension 5)History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 6)Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits. 7)End stage renal disease 8)Symptomatic (NYHA III or IV) congestive heart failure 9)Malignancies or other diseases with poor prognosis 10)Pregnant 11)Subjects whose doctor in charge do not agree to join the trial |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Katsunori Ikewaki |
| Organization | National Defense Medical College |
| Division name | Department of Internal Medicine I |
| Address | 3-2 Namiki, Tokorozawa, JAPAN 359-8513 |
| TEL | 04-2995-1597 |
| katsunorike@ndmc.ac.jp | |
| Public contact | |
| Name of contact person | Makoto Ayaori |
| Organization | National Defense Medical College |
| Division name | Department of Internal Medicine I |
| Address | 3-2 Namiki, Tokorozawa, JAPAN 359-8513 |
| TEL | 04-2995-1597 |
| Homepage URL | |
| ayaori@ndmc.ac.jp | |
| Sponsor | |
| Institute | National Defense Medical College |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Foundation for Promotion of Defense Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 防衛医科大学校 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003402 |